Tada Satoru, Kaito Yuta, Watanabe Akihiro, Sugiyama Yukio, Nishigaichi Akira, Miwa Takashi, Watanabe Kotaro, Hazama Takanori, Takahashi Daisuke
Department of Neurology, Osaka University Graduate School of Medicine, Osaka, JPN.
Department of Neurology, National Hospital Organization Osaka Minami Medical Center, Osaka, JPN.
Cureus. 2024 Feb 23;16(2):e54775. doi: 10.7759/cureus.54775. eCollection 2024 Feb.
Varicella-zoster virus (VZV), known for causing chickenpox, establishes latent infections in neural tissues. Reactivation of VZV can lead to herpes zoster (HZ) and various neurological complications. In this report, we present four cases of VZV meningitis and myelitis following amenamevir treatment for HZ dermatitis with positive VZV DNA in cerebrospinal fluid (CSF) revealed by polymerase chain reaction (PCR). Three of them were considered immunocompromised hosts given the fact that two of these patients were taking immunosuppressive drugs for rheumatoid arthritis, and one patient had a history of sigmoid colon cancer (four months after resection). After HZ onset, amenamevir, which has poor CSF transfer, was prescribed for all the patients, and all of them developed central nervous complications by VZV (meningitis in three cases and myelitis in one case) confirmed by PCR. All the patients were treated with acyclovir, which has a higher CSF transfer, and fully recovered. We speculate that amenamevir might have failed to prevent VZV infection in the central nervous system (CNS) and think that consideration should be given to administering acyclovir in preference to amenamevir for ΗΖ patients at high risk of CNS VZV infection, such as immunocompromised hosts.
水痘带状疱疹病毒(VZV)以引起水痘而闻名,可在神经组织中建立潜伏感染。VZV的重新激活可导致带状疱疹(HZ)和各种神经并发症。在本报告中,我们介绍了4例在使用阿昔洛韦治疗HZ性皮炎后发生VZV脑膜炎和脊髓炎的病例,通过聚合酶链反应(PCR)检测发现脑脊液(CSF)中VZV DNA呈阳性。其中3例被认为是免疫功能低下宿主,因为其中2例患者正在服用治疗类风湿性关节炎的免疫抑制药物,1例患者有乙状结肠癌病史(切除术后4个月)。HZ发病后,所有患者均服用了脑脊液通透性较差的阿昔洛韦,所有患者均出现了经PCR证实的由VZV引起的中枢神经系统并发症(3例脑膜炎,1例脊髓炎)。所有患者均接受了脑脊液通透性较高的阿昔洛韦治疗,并完全康复。我们推测阿昔洛韦可能未能预防中枢神经系统(CNS)的VZV感染,并认为对于有CNS VZV感染高风险的HZ患者,如免疫功能低下宿主,应优先考虑使用阿昔洛韦而非阿昔洛韦进行治疗。